Nilotinib: the other phase II trial

This article describes how nilotinib, a drug approved by the FDA for treatment of leukemia, may be an effective and potentially disease modifying treatment for Parkinson's Disease based on animal studies and a phase I trial in humans. The drug is now entering phase II clinical trials.

Click here to view the article